Address: C Calle 93 B #17–25/49, Piso 5
Bogotá, Colombia
Tel: + 57 1 621 6600
Web: http://www.genzyme.com.co/default_co.asp
Genzyme de Colombia S.A., a subsidiary of Genzyme Corporation, is a growing organization that began its first activities in the country in 1996 through an external consultant for the purpose of registering Ceredase ®, the enzyme for treating Gaucher disease.
Since then, Genzyme de Colombia S.A.’s commitment has been to the continued support of patients, families and health specialists involved with the comprehensive management of lysosomal storage diseases.
It is Genzyme de Colombia S.A.’s mission to collaborate fully for the best quality and life expectancy of all patients in both Colombia and the Andean Pact affected by these diseases and who require on our part a sense of urgency that is present in all our employees.
From the moment Genzyme de Colombia S.A.’s began operations, even before the formal establishment of Genzyme de Colombia SA, the company has been working hard in deepening the knowledge within the medical profession of these diseases, which although of low incidence, significantly impact the patients affected by them.
Support for the medical community and health system in the best knowledge and comprehensive treatment of these diseases resulted in the formal establishment of Genzyme de Colombia S.A. in April 2002.
In July 1998 Genzyme de Colombia S.A. obtained the medical records for Cerezyme ® the first recombinant enzyme approved by the FDA for the treatment of Gaucher disease. In addition Genzyme de Colombia S.A. is currently marketing in Colombia Fabrazyme ® and Aldurazyme ®, the two recombinant enzymes approved by the FDA and the EMEA for the treatment of Fabry disease and MPS1 (Mucopolysaccharidosis 1), respectively.
Similarly, Genzyme de Colombia S.A. has a regional team committed to supporting patients with chronic renal failure and transplantation. We have obtained registration in Colombia for Renagel ® (sevelamer) for the treatment of phosphorus in dialysis patients.
Rare genetic disorders, kidney disease, osteoarthritis, and immunological diseases.
Juan Gabriel Pérez, Executive Director of Invest in Bogota, shares his powerful message of why Bogota is an ideal investment destination, not only relative to other Colombian cities, but to…
Aurobindo’s regional head, Kamlesh Thakkar, discusses how the company is truly benefiting the healthcare landscape in Colombia, while describing his experience in changing the mindset concerning the use of generics…
Regional leader of Boston Scientific’s Andean Region, Fernando Dussan, share his insights on why Colombia is suitable to host the core business of Boston Scientific. He speaks about the company’s…
Spearheading the Colombian affiliate of the global leader in oncology, Carlos Estrada, General Manager of Roche Colombia shares his insights on the profound transformations of the Colombian healthcare system. He…
The executive director of the AmCham Colombia shares his insights on the legacy of strong economic ties between the two countries. He speaks about the changing socio-political landscape of Colombia,…
Executive Director of the French-Colombian Chamber of Commerce and Industry, Victor Brun, shares his insights regarding the solid Franco-Colombo relations. He speaks about the synergies between the two cultures, the…
PharmaBoardroom spoke to Fabrice Chouraqui, President of Novartis Latin America and Canada at the Financial Times LatAm Healthcare & Life Sciences Summit in September 2015. He emphasizes the criticality of…
The founder and general manager of Biotechnova considers the potential of Colombia for biotechnological innovation, and explains the current state of the biogeneric industry in Latin America. Please start by…
Medical devices are one of the most profitable niches in Colombian health. Marisol Sanchez, president of the Camara de Proveedores de Salud, notes that “the medical device sector correlated to…
President Santos appointed economist Alejandro Gaviria as the new Minister of Health and Social Protection in September 2012. Gaviria’s priority has been to create health reform that would introduce…
Under the administration of President Juan Manuel Santos, Colombia is focusing on bolstering the commercial sector. Thanks to the ratification of free trade agreements with 14 countries around the…
Carlos Manuel González Parra discusses the progress Novo Nordisk has made as a newcomer to the Colombian market and its hopes and intentions for the future. One of the main…
See our Cookie Privacy Policy Here
